Loading people...
Dimitri Krainc is a Venture Partner at OrbiMed and the Aaron Montgomery Ward Professor and Chairman of the Department of Neurology at Northwestern University Feinberg School of Medicine, based in Chicago, Illinois. Before joining Northwestern, he spent over two decades at Massachusetts General Hospital and Harvard Medical School, where he completed his neurology residency in 2000 and fellowship in 2002. As a biotechnology entrepreneur, he founded Lysosomal Therapeutics, which was acquired by Bial, and Vanqua Bio, a startup that secured an $85 million Series B financing in 2021. He holds an MD from the University of Zagreb and a PhD from Harvard University, and was elected to the National Academy of Medicine in 2023. His career focuses on bridging academic neuroscience research with venture capital to develop targeted therapeutics for neurodegenerative conditions like Parkinson's disease.
Dimitri Krainc is a distinguished Venture Partner at OrbiMed, one of the world's largest and most active healthcare-dedicated investment firms. OrbiMed is renowned for its deep expertise across the healthcare spectrum, from venture capital to public equity, and Krainc's role is pivotal in its early-stage investment strategy. He focuses on identifying groundbreaking opportunities within the life sciences, particularly in biotechnology, pharmaceuticals, and medical devices.
As a Venture Partner, Dimitri Krainc leverages his extensive industry knowledge to evaluate potential investments, conduct due diligence, and provide strategic guidance to portfolio companies. His work is instrumental in fostering the growth of innovative startups that aim to address significant unmet medical needs and advance patient care. He collaborates closely with entrepreneurs and scientific founders, helping to translate cutting-edge research into viable commercial products and therapies.
Krainc's career background likely includes significant experience in the healthcare and life sciences industries, possibly spanning roles in research and development, business development, or executive leadership within biotech or pharmaceutical companies. This hands-on experience provides him with a unique perspective on the challenges and opportunities faced by early-stage companies, enabling him to offer invaluable insights and mentorship. His strategic input helps companies navigate complex regulatory landscapes, secure further funding, and achieve key milestones.
While specific notable investments are often part of a firm's collective portfolio, Dimitri Krainc's involvement contributes to OrbiMed's track record of backing successful ventures that have brought novel treatments and technologies to market. His focus areas typically include therapeutic platforms, novel drug discovery, diagnostics, and innovative medical technologies that promise to disrupt existing paradigms or create new ones. Through his work at OrbiMed, Krainc continues to shape the future of healthcare by supporting the next generation of life sciences innovators.
Dimitri Krainc is a Venture Partner at OrbiMed, a leading global healthcare investment firm. He specializes in early-stage investments within the life sciences sector, including biotechnology, pharmaceuticals, and medical technology.
Dimitri Krainc primarily invests in early-stage companies within the healthcare and life sciences industries. His focus areas include biotechnology, pharmaceuticals, medical devices, and other innovative therapeutic platforms.
Dimitri Krainc works as a Venture Partner at OrbiMed, a prominent healthcare-dedicated investment firm with a global presence.
